Send to

Choose Destination
MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14.

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Author information

a Laboratory of Translational Immunology; UMC Utrecht ; Utrecht , The Netherlands.
b Center for Proteomics and Metabolomics; Leiden University Medical Center ; Leiden , The Netherlands.
c Department of Pathology ; UMC Utrecht ; Utrecht , The Netherlands.
d Division of Stem Cell Transplantation and Immunotherapy ; Department of Internal Medicine II; Christian-Albrechts-University ; Kiel , Germany.
e Synthon Biopharmaceuticals BV ; Nijmegen , The Netherlands.

Erratum in


Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that engages FcαRI expressing myeloid effector cells, such as neutrophils and monocytes. IgA Abs have been shown to effectively kill tumor cells both in vitro and in vivo. However, due to the short half-life of IgA Abs in mice, daily injections are required to reach an effect comparable to IgG Abs. The relatively long half-life of IgG Abs and serum albumin arises from their capability of interacting with the neonatal Fc receptor (FcRn). As IgA Abs lack a binding site for FcRn, we generated IgA Abs with the variable regions of the Her2-specific Ab trastuzumab and attached an albumin-binding domain (ABD) to the heavy or light chain (HCABD/LCABD) to extend their serum half-life. These modified Abs were able to bind albumin from different species in vitro. Furthermore, tumor cell lysis of IgA-Her2-LCABD Abs in vitro was similar to unmodified IgA-Her2 Abs. Pharmacokinetic studies in mice revealed that the serum exposure and half-life of the modified IgA-Her2 Abs was extended. In a xenograft mouse model, the modified IgA1 Abs exhibited a slightly, but significantly, improved anti-tumor response compared to the unmodified Ab. In conclusion, empowering IgA Abs with albumin-binding capacity results in in vitro and in vivo functional Abs with an enhanced exposure and prolonged half-life.


Fc a receptor (FcaRI); IgA; albumin-binding domain (ABD); antibody therapy; glycosylation; half-life extension; neonatal Fc receptor (FcRn); serum exposure

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center